Emerald Clinics Ltd (ASX: EMD) has entered into a clinical trial research agreement to accelerate the completion of the Zelira sponsored trial at St Vincent’s Hospital in Melbourne.
Zelira Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) has now fully enrolled its Phase 1 Dose Escalation
Trial in patients on long-term opioid treatment.
The trial is called “A study to evaluate the safety, tolerability, and pharmacokinetics of a medicinal cannabinoid oil formulation in chronic non-cancer pain participants on long term opioid treatments.”
No serious adverse events from dosing patients have been reported to date and dosing is expected to be completed by April 2020.
Zelira pleased to expand partnership with Emerald Clinics
Emerald Clinics’ managing director and CEO Dr Michael Winlo said: “We are pleased to be working with Zelira, who are investing in the rigorous, product-specific clinical studies required to bring cannabinoid-based medical products into the mainstream where appropriate.
“Undertaking this trial validates our model of co-creating evidence with our patients while providing high-quality care.
“We are excited to be building upon the collaboration announced in 2019 and look forward to leveraging Real World Evidence (RWE) and traditional clinical trials to support Zelira’s strategy and ultimately improve the health and wellbeing of our patients.”
Zelda’s managing director Dr Richard Hopkins said: “We’re also pleased for the opportunity to expand our partnership with Emerald Clinics by bringing them on as a second site.
“We have been impressed by their ability to complement the efforts of the St Vincent team by rapidly screening and enrolling eligible patients into trial.
Trial could be first of its kind
“To our knowledge, this is the first clinical trial to be designed with a primary end-point assessing the efficacy of a full spectrum plant-derived cannabis formulation containing THC and CBD to reduce opioid dependence in chronic non-cancer patients.